Real-World Evidence of Aripiprazole Tablets with Sensor: Treatment Patterns and Impacts on Psychiatric Healthcare Resource Utilization
Dusica Hadzi Boskovic,1 Shuting Liang,2 Purva Parab,2 Emily Wiggins,2 Joshua N Liberman2 1Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA; 2Health Analytics, LLC, Clarksville, MD, USACorrespondence: Dusica Hadzi Boskovic, Otsuka Pharmaceutical Development & Co...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_965d9d0b71bc42cfa9a0e4ad79fc4fd3 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Hadzi Boskovic D |e author |
700 | 1 | 0 | |a Liang S |e author |
700 | 1 | 0 | |a Parab P |e author |
700 | 1 | 0 | |a Wiggins E |e author |
700 | 1 | 0 | |a Liberman JN |e author |
245 | 0 | 0 | |a Real-World Evidence of Aripiprazole Tablets with Sensor: Treatment Patterns and Impacts on Psychiatric Healthcare Resource Utilization |
260 | |b Dove Medical Press, |c 2023-06-01T00:00:00Z. | ||
500 | |a 1178-6981 | ||
520 | |a Dusica Hadzi Boskovic,1 Shuting Liang,2 Purva Parab,2 Emily Wiggins,2 Joshua N Liberman2 1Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA; 2Health Analytics, LLC, Clarksville, MD, USACorrespondence: Dusica Hadzi Boskovic, Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center, Princeton, NJ, 08540, USA, Tel +1 6468122719, Email Dusica.HadziBoskovic@otsuka-us.comPurpose: Maintaining adherence to antipsychotic (AP) medication is often challenging. Aripiprazole tablets with sensor (AS) contain an ingestible event marker and communicate with wearable patches and a smartphone app to provide objective medication ingestion data. This study evaluated real-world treatment patterns of AS usage and its impact on psychiatric healthcare resource utilization (HCRU).Patients and Methods: This retrospective, observational cohort study identified individuals who initiated AS between 1/1/2019 and 6/30/2020 with 3 months baseline and 6 months of follow-up data using a commercial medical and pharmacy claims database (Clarivate). Controls were propensity score-matched (4:1) to AS initiators based on age (± 2 years), sex, diagnosis (major depressive disorder [MDD], schizophrenia, bipolar I disorder [BP-I], other), insurance, and baseline oral AP use (yes/no). Days of AP supply were evaluated using a general regression model. The frequency of psychiatric HCRU during follow-up was compared between groups using a zero-inflated regression model.Results: Most AS initiators were diagnosed with MDD (61.2%) and were women (61.2%); mean age was 37.7 years (standard deviation: 14.1). Most AS initiators (53.1%) continued treatment for > 60 days (mean days of supply = 77). After adjusting for covariates, AS initiators had 41% more days of AP supply during follow-up compared with controls (P < 0.0001) and significantly lower adjusted odds ratios (ORs) for psychiatric outpatient visits (adjusted OR = 0.80; P < 0.05), emergency department visits (adjusted OR = 0.11; P < 0.05), inpatient visits (adjusted OR = 0.42; P < 0.05), and other medical services (adjusted OR = 0.25; P < 0.05).Conclusion: Participants who implemented AS had significantly more days of AP supply and fewer psychiatric care visits. These preliminary results suggest AS usage can help build regular medication-taking habits and holds promise for reducing psychiatric HCRU. Additional studies with larger sample sizes are warranted to inform clinical practice and coverage decisions.Keywords: serious mental illness, digital medicine system, digital health, clinical decision-making | ||
546 | |a EN | ||
690 | |a serious mental illness | ||
690 | |a digital medicine system | ||
690 | |a digital health | ||
690 | |a clinical decision-making | ||
690 | |a Medicine (General) | ||
690 | |a R5-920 | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n ClinicoEconomics and Outcomes Research, Vol Volume 15, Pp 487-498 (2023) | |
787 | 0 | |n https://www.dovepress.com/real-world-evidence-of-aripiprazole-tablets-with-sensor-treatment-patt-peer-reviewed-fulltext-article-CEOR | |
787 | 0 | |n https://doaj.org/toc/1178-6981 | |
856 | 4 | 1 | |u https://doaj.org/article/965d9d0b71bc42cfa9a0e4ad79fc4fd3 |z Connect to this object online. |